GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Current Deferred Revenue

NLS Pharmaceutics (NLS Pharmaceutics) Current Deferred Revenue : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

NLS Pharmaceutics's current deferred revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

NLS Pharmaceutics Current Deferred Revenue Historical Data

The historical data trend for NLS Pharmaceutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Current Deferred Revenue Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NLS Pharmaceutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Current Deferred Revenue
Comparable Companies
UNCY NBIO AIM SKYE ELEV ACST NTBL BIXT VINC ACER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
Website
https://www.nlspharma.com
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.